CRLF2 and acute lymphoblastic leukemia: Conversely, concurrent co-administration of ruxolitinib diminished TSLPRCART-mediated inhibition of in vivo CRLF2+ ALL proliferation (Fig. 1B, green), T cell expansion in peripheral blood (Fig. 1C, green), and IFN-γ production (Fig. 1D, green).